Urinary concentrations of morphine and codeine after consumption of poppy seedsAnalytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry.Identification and quantification of the plasma volume expander dextran in human urine by liquid chromatography-tandem mass spectrometry of enzymatically derived isomaltose.Mapping the interaction of cofilin with subdomain 2 on actin.Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing.Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry.Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis.Examples of doping control analysis by liquid chromatography-tandem mass spectrometry: ephedrines, beta-receptor blocking agents, diuretics, sympathomimetics, and cross-linked hemoglobins.Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry.Mass spectrometry in sports drug testing: Structure characterization and analytical assays.Liquid chromatographic-mass spectrometric analysis of glucuronide-conjugated anabolic steroid metabolites: method validation and interlaboratory comparison.Doping control analysis of methoxyphenamine using liquid chromatography-tandem mass spectrometry.Analysis of selective androgen receptor modulators by gas chromatography-microchip atmospheric pressure photoionization-mass spectrometry.Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254.Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes.Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015.Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing.Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.Analysis of octopamine in human doping control samples.Mildronate (Meldonium) in professional sports - monitoring doping control urine samples using hydrophilic interaction liquid chromatography - high resolution/high accuracy mass spectrometry.Structure elucidation of the diagnostic product ion at m/z 97 derived from androst-4-en-3-one-based steroids by ESI-CID and IRMPD spectroscopy.Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet.Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits.Metabolism of growth hormone releasing peptides.Annual banned-substance review: analytical approaches in human sports drug testing.Evaluation of AMGEN clone 9G8A anti-Epo antibody for application in doping control.Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.Determination of tuaminoheptane in doping control urine samples.RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability.Temporal indication of cannabis use by means of THC glucuronide determination.Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.Mass spectrometry of hydantoin-derived selective androgen receptor modulators.Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS.Factors influencing the steroid profile in doping control analysis.Detection of recombinant growth hormone in human plasma by a 2-D PAGE method.Doping control analysis of metamfepramone and two major metabolites using liquid chromatography-tandem mass spectrometry.Obesity resistance and deregulation of lipogenesis in Δ6-fatty acid desaturase (FADS2) deficiency.Complementing the characterization of in vivo generated N-glucuronic acid conjugates of stanozolol by collision cross section computation and analysis.
P50
Q28209611-46BACAB0-DA47-436D-87B9-BBAAD1260765Q30390786-897E6443-D7D6-41F2-AD16-0124BBEAFD3DQ31164243-40A1F081-6153-4506-9E7A-7C6B62AF7D52Q33267993-64C1992D-D423-4E7C-A85D-14E6A0F7BB75Q33313601-2F2BB2ED-DBB9-4AC3-AE5A-1BE2BE8340F2Q33324266-2C8FA8CF-32CF-4D85-A94D-69D360447208Q33431949-A12C8A9A-5957-4735-840D-518F4BA50996Q33433141-D4D1F803-8F9E-4368-96E8-149CDD483A3DQ33434659-DBD4EC0E-BC59-4E8A-AA4B-088E1E4128EEQ33435735-80F26DAF-7184-4AD5-BEE8-F77953C9A0CBQ33440073-BDBDF60E-723B-464A-8687-00C50CAC8239Q33440529-7E5E0D31-03F8-490C-A382-06ECA8C453A3Q33444607-051DAE1E-194D-4928-BF6B-F61BA4BC668EQ33467518-89A93C29-6A3A-41CD-9D56-35564528FCC6Q33468414-BC264DC0-8846-4E56-9F4A-A03BCCB02B9FQ33659488-E2B60644-BBBF-48DA-8CB0-1B44FE9452D9Q33859587-7A7CCDC8-47F1-4716-998E-559AB2A2BDF1Q33944531-53E5B9AE-1AA0-4F1F-BED6-DA9230A498F2Q34024311-EC618A20-3DD9-4ACD-9A2C-4D17D138AEBBQ34043669-97E12D18-7034-48C2-B813-295CC4A22AB6Q34102510-4CD3DED6-0C89-4F2D-84D9-4BBE4C228794Q34169514-316A0652-95A2-4373-B55B-282B65D74995Q34182103-64AF56AB-A09D-433E-BCF8-9350D7100264Q34424169-BB97708B-B058-4CD7-B2EA-503E1B5B889EQ34458391-4E650F0B-9157-4814-A7B6-F66B334D98DEQ34509038-FF2122A4-F7BE-4901-804E-0B7D00508A98Q34538186-6434D67B-C48D-451E-9AD3-0AFC9A985FB2Q34567702-B5C49610-DF38-470E-A85F-FA4B0EC63AACQ34575235-DD198CEF-D9DF-4AD8-B428-A4C5E7DCC32CQ34583136-1636BC2B-0FFD-414E-B704-1CF3E9A71480Q34592919-36A9E6A2-732A-4069-8664-9ADC93BFC1D2Q34618371-D0C78F9E-C310-463D-9F1E-3AE50786078BQ34710698-7BB2C30B-45AF-493E-B5B8-20A8CEDB4BB7Q34728033-E85F97BE-9E6D-4C8F-B9C3-E500F79C6D30Q34749565-5941913E-4BB2-412C-A218-F1176210079EQ34788041-0C504C10-4C3C-49EA-878E-95298C32DD73Q34878291-384E18AD-EAF2-48E8-A0DA-951774DC035CQ34996085-EBB715B1-F7E4-4FE4-B185-04AE34468F35Q35001747-A8A01210-9A27-4254-B1A1-5D4C7CDA6470Q35826591-44C4C54D-841D-454C-B0A6-59191EB84671
P50
description
deutscher Chemiker, Sportwissenschaftler und Hochschullehrer
@de
scheikundige
@nl
name
Mario Thevis
@ast
Mario Thevis
@de
Mario Thevis
@en
Mario Thevis
@nl
Mario Thevis
@sl
type
label
Mario Thevis
@ast
Mario Thevis
@de
Mario Thevis
@en
Mario Thevis
@nl
Mario Thevis
@sl
prefLabel
Mario Thevis
@ast
Mario Thevis
@de
Mario Thevis
@en
Mario Thevis
@nl
Mario Thevis
@sl
P214
P227
P244
P5361
P106
P19
P21
P213
0000 0001 1490 1705
P214
P227
P244
n2009185542
P31
P5361
ThevisMario1973-
P569
1973-05-15T00:00:00Z
P7859
lccn-n2009185542